Alexis Minaudo

Alexis Minaudo supports the National Cancer Institute’s mission by managing critical procurement initiatives focused on advanced biomedical software and computational research services. Though their formal title is not publicly designated, their role centers on executing complex acquisitions for data-driven cancer research infrastructure, including genomic analysis platforms, clinical decision support systems, and custom bioinformatics tools. Minaudo ensures alignment with NIH’s strategic goals by facilitating contracts that enable high-performance computing, machine learning applications, and precision medicine technologies—directly supporting translational research pipelines at the intersection of oncology and information science. Minaudo maintains a primary working relationship with Roche Diagnostics Corporation, a leading provider of integrated diagnostic and genomic solutions. Their contracting patterns reflect a preference for established industry partners with proven capabilities in clinical data management, laboratory information systems, and scalable software platforms. These vendor relationships are characterized by long-term, performance-based engagements that prioritize technical rigor, regulatory compliance, and interoperability with NIH’s research ecosystems. Minaudo’s acquisition portfolio exhibits no reliance on socioeconomic set-asides, with 100% of awards issued under full and open competition. This reflects a mission-driven focus on securing the highest-capability solutions regardless of vendor size, prioritizing technical excellence and scalability over socioeconomic preferences. While small business participation is not formally incentivized, the nature of the procurements often attracts innovative firms capable of delivering specialized computational services. The core NAICS focus areas—513210 (Software Publishers), 541511 (Custom Computer Programming Services), and 541519 (Other Computer-Related Services)—reveal a deep specialization in bespoke bioinformatics software, data analytics pipelines, and cloud-enabled research platforms. Minaudo consistently procures solutions that support high-throughput sequencing, AI-driven tumor profiling, and real-time clinical data integration, positioning them at the forefront of cancer research technology acquisition.